In collaboration with MMV, based in Switzerland, Cipla and Strides Arcolab venture to develop rectal artesunate for pre-referral malaria treatment severe in children.
The MMV-led project is UNITAID funded and intend to submit a rectal artesunate product to WHO World Health Organisation. A 5.6 million cases have been estimated for severe malaria every year and results to 627,000 deaths and it includes mostly children under five years.
"We have agreed a clear pathway with these two manufacturers to bring this product to an internationally acceptable quality standard. This will help make the product available to more patients, buying more time and saving more lives," MMV CEO David Reddy said.